OBIOOrchestra BioMed Holdings, Inc.

OBIO Stock Price, Valuation & Chart | Orchestra BioMed Holdings, Inc.

Compare

$4.950+0.05 (+1.02%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology OBIO intrinsic value OBIO calculated fair value vs price

Overview Financials Dividends Ratios

OBIO Historical price chart

OBIO Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization296.41M

PE Ratio-5.1

EPS-0.97

Trading Volume240.38K

Today's High/Low5.01/4.83

Dividend Yield0.00

52 Week High/Low5.78/2.2

Shares Outstanding59.88M

OBIO Financial Statement

OBIO Analyst ratings

OBIO Analysis & performance metrics

OBIO Company profile

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT)…

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive…

OBIO Management team

Name

Position

Juan Lorenzo

Senior Vice President of Product Development

William Reed Little

Executive Vice President of Corporate Development & Strategy

Mark Pomeranz

GM & Executive Vice President of Interventional Therapies

Hans-Peter Stoll M.D., Ph.D.

Chief Clinical Officer

Yuval Hay Mika D.Sc, Ph.D.CTO

GM & Chief Technology Officer of Bioelectronic Therapies

David P. HochmanCEO

Founder, Chairman of the Board of Directors & Chief Executive Officer

Darren R. ShermanCOO

Founder, President, Chief Operating Officer & Director

Andrew Lawrence Taylor M.B.A.CFO

Chief Financial Officer

Name

Position

Juan Lorenzo

Senior Vice President of Product Development

William Reed Little

Executive Vice President of Corporate Development & Strategy

Mark Pomeranz

GM & Executive Vice President of Interventional Therapies

Hans-Peter Stoll M.D., Ph.D.

Chief Clinical Officer

Yuval Hay Mika D.Sc, Ph.D.CTO

GM & Chief Technology Officer of Bioelectronic Therapies

David P. HochmanCEO

Founder, Chairman of the Board of Directors & Chief Executive Officer

Darren R. ShermanCOO

Founder, President, Chief Operating Officer & Director

Andrew Lawrence Taylor M.B.A.CFO

Chief Financial Officer

Management Team

Juan Lorenzo

Senior Vice President of Product Development

William Reed Little

Executive Vice President of Corporate Development & Strategy

Mark Pomeranz

GM & Executive Vice President of Interventional Therapies

Hans-Peter Stoll M.D., Ph.D.

Chief Clinical Officer

Yuval Hay Mika D.Sc, Ph.D.CTO

GM & Chief Technology Officer of Bioelectronic Therapies

David P. HochmanCEO

Founder, Chairman of the Board of Directors & Chief Executive Officer

Darren R. ShermanCOO

Founder, President, Chief Operating Officer & Director

Andrew Lawrence Taylor M.B.A.CFO

Chief Financial Officer

Management

Juan Lorenzo

Senior Vice President of Product Development

William Reed Little

Executive Vice President of Corporate Development & Strategy

Mark Pomeranz

GM & Executive Vice President of Interventional Therapies

Hans-Peter Stoll M.D., Ph.D.

Chief Clinical Officer

Yuval Hay Mika D.Sc, Ph.D.CTO

GM & Chief Technology Officer of Bioelectronic Therapies

David P. HochmanCEO

Founder, Chairman of the Board of Directors & Chief Executive Officer

Darren R. ShermanCOO

Founder, President, Chief Operating Officer & Director

Andrew Lawrence Taylor M.B.A.CFO

Chief Financial Officer

Total 8 executives

OBIO Frequently asked questions

What is Orchestra BioMed Holdings, Inc. (OBIO) Stock Price?

Current stock price of Orchestra BioMed Holdings, Inc. (OBIO) stock is $4.950. The stock price is +1.02% higher in the session. The intraday range can be seen from this page. Volume of Orchestra BioMed Holdings, Inc. (OBIO) stock is 240.38K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Orchestra BioMed Holdings, Inc. (OBIO) stock price going up or down today?

The stock price of Orchestra BioMed Holdings, Inc. (OBIO) can change with earnings, company news, and overall market sentiment. Orchestra BioMed Holdings, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Orchestra BioMed Holdings, Inc. stock expensive at its current price?

Whether Orchestra BioMed Holdings, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for OBIO on this page is -5.10. EPS on this page is -0.97. Compare those figures with peers and growth expectations before deciding if the current Orchestra BioMed Holdings, Inc. price is justified.

How has the stock price of Orchestra BioMed Holdings, Inc. (OBIO) performed historically?

Historical performance for Orchestra BioMed Holdings, Inc. (OBIO) is shown on the price chart on this page. Review multi-period moves alongside volume to see how OBIO reacted to past earnings and market events.

Should I buy Orchestra BioMed Holdings, Inc. (OBIO) stock, at this price?

Buying Orchestra BioMed Holdings, Inc. (OBIO) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.